I-Candesartan CAS 139481-59-7 Ubumsulwa >99.0% (HPLC) Factory
I-Ruifu Chemical Supply Candesartan Cilexetil Intermediate With High Purity
I-Candesartan Cilexetil CAS 145040-37-5
I-Candesartan CAS 139481-59-7
I-1-Chloroethyl Cyclohexyl Carbonate CAS 99464-83-2
Candesartan Cilexetil Intermediate Eethyl Ester C6 CAS 139481-41-7
I-Candesartan Cilexetil I-CAS 139481-44-0
I-Trityl Candesartan Cilexetil CAS 170791-09-0
Igama Lekhemikhali | I-Candesartan |
Omqondofana | I-CV-11974;I-2-Ethoxy-1-[[2'- (1H-tetrazol-5-yl) [1,1'-biphenyl] -4-yl]methyl]-1H-Benzimidazole-7-Carboxylic Acid;3--[[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl]-2-ethoxy-3H-Benzimidazole-4-Carboxylic Acid;I-Candesartan M1;Candesartan Cilexetil EP Impurity G |
Inombolo ye-CAS | 139481-59-7 |
Inombolo yeCAT | I-RF-PI1889 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
I-Molecular Formula | I-C24H20N6O3 |
Isisindo samangqamuzana | 440.45 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | Impushana Emhlophe |
Identification-HPLC | Isikhathi Sokugcina Esifana Nesejwayelekile |
Ukuhlonza-IR | Kufana ne-Standard |
Ukuhlanzeka / Indlela Yokuhlaziya | >99.0% (HPLC) |
I-Melting Point | 183.0~185.0℃ |
Ukulahlekelwa Ekumisweni | <0.50% |
Umswakama (KF) | <0.50% |
Izinsalela ekushiseni | <0.50% |
Izinsimbi Ezisindayo | <20ppm |
Ukungcola Ngamunye | <1.00% (HPLC) |
Ukungcola Okuphelele | <1.00% (HPLC) |
I-Refractive Index | n20/D 1.745~1.747 |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | I-API;Okokwelapha I-Hypertension |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-Candesartan (i-CAS: 139481-59-7) iyisamukeli se-angiotensin II esine-IC50 ka-0.26 nM.Okuhlosiwe: I-Angiotensin II Receptor candesartan ikhonjiswe ekwelapheni umfutho wegazi ophakeme.I-Candesartan Cilexetil yavunywa okokuqala nge-GB ngo-Apr 29, 1997, yabe isigunyazwa yi-US Food and Drug Administration (FDA) ngoJuni 4, 1998, futhi yavunyelwa i-Pharmaceuticals and Medical Devices Agency of Japan (PMDA) ngo-Mar 12, 1999. Yathuthukiswa ngabakwa-AstraZeneca, yase imakethwa njenge-Atacand yi-AstraZeneca nge-GB nase-US, futhi imakethwa njenge-Blopress ngu-Takeda e-JP.I-Candesartan Cilexetil iyi-angiotensin II receptor blocker (ARB), ivimba imiphumela ye-vasoconstrictor kanye ne-aldosterone-secreting ye-angiotensin II ngokuvimbela ngokukhetha ukuboshwa kwe-angiotensin II ku-AT1 receptor ezicutshini eziningi, njenge-vascular smooth muscle kanye ne-adrenal gland.I-Atacand ikhonjiswe ekwelapheni umfutho wegazi ophakeme kubantu abadala kanye nezingane ezineminyaka engu-1 kuya kwezingu-17 ubudala, ukwehluleka kwenhliziyo (isigaba se-NYHA II-IV) futhi isetshenziselwe ukunciphisa ukufa kwenhliziyo nemithambo yegazi nokulaliswa esibhedlela.